or
forgot password

Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer: A Pilot Study


N/A
40 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer: A Pilot Study


Inclusion Criteria:



- Postmenopausal women with diagnosis of breast cancer - have not started Arimidex or
Femara yet, but will be starting .

Exclusion Criteria:

- History of metastasis

- History of chronic kidney

- Liver GI disease

- Disorders affecting calcium metabolism

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

bone density

Outcome Time Frame:

baseline, 6 months, 12 months

Safety Issue:

Yes

Principal Investigator

Pamela Taxel, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Connecticut Health Center

Authority:

United States: Institutional Review Board

Study ID:

07-043-2

NCT ID:

NCT00762294

Start Date:

May 2007

Completion Date:

December 2011

Related Keywords:

  • Breast Cancer
  • breast cancer
  • arimidex
  • femara
  • bone health
  • Breast Neoplasms

Name

Location
University of Connecticut Health Center Farmington, Connecticut  06360-7106